Evidence map›Paper›PMID 35242773›Full record

ArticleFrontiers in medicine2022

Validation of the International IgA Nephropathy Prediction Tool in the Greek Registry of IgA Nephropathy.

Marios Papasotiriou, Maria Stangou, Dimitris Chlorogiannis, Smaragdi Marinaki, Dimitrios Xydakis, Erasmia Sampani, Georgios Lioulios, Eleni Kapsia, Synodi Zerbala, Maria Koukoulaki and 15 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.7field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 11 institutions in 1 country.

Marios PapasotiriouDepartment of Nephrology and Kidney Transplantation, University Hospital of Patras, Patras, Greece.
Maria StangouDepartment of Nephrology, Hippokration General Hospital, Aristotle University of Thassaloniki, Thessaloniki, Greece.
Dimitris ChlorogiannisDepartment of Medical Physics and Bioinformatics, University of Patras, Patras, Greece.
Smaragdi MarinakiDepartment of Nephrology and Kidney Transplantation, Laiko General Hospital of Athens, National and Kapodistrian University of Athens Medical School, Athens, Greece.
Dimitrios XydakisDepartment of Nephrology, General Hospital of Heraklion "Venizeleio-Pananeio", Heraklion, Greece.
Erasmia SampaniDepartment of Nephrology, Hippokration General Hospital, Aristotle University of Thassaloniki, Thessaloniki, Greece.
Georgios LiouliosDepartment of Nephrology, Hippokration General Hospital, Aristotle University of Thassaloniki, Thessaloniki, Greece.
Eleni KapsiaDepartment of Nephrology and Kidney Transplantation, Laiko General Hospital of Athens, National and Kapodistrian University of Athens Medical School, Athens, Greece.
Synodi ZerbalaDepartment of Nephrology, General Hospital of Nikaia, Piraeus, Greece.
Maria KoukoulakiDepartment of Nephrology, General Hospital of Nikaia, Piraeus, Greece.
Georgios MoustakasDepartment of Nephrology, Gennimatas General Hospital of Athens, Athens, Greece.
Stavros FokasDepartment of Nephrology, Gennimatas General Hospital of Athens, Athens, Greece.
Evangelia DounousiDepartment of Nephrology, School of Medicine, University of Ioannina, Ioannina, Greece.
Anila DuniDepartment of Nephrology, School of Medicine, University of Ioannina, Ioannina, Greece.
Antonia PapadakiDepartment of Nephrology, General Hospital of Chania, Chania, Greece.
Nikolaos DamianakisDepartment of Nephrology, General Hospital of Chania, Chania, Greece.
Dimitra BacharakiSecond Department of Internal Medicine-Propaedeutic, Research Institute and Diabetes Centre, Attikon University Hospital, National and Kapodistrian University of Athens Medical School, Athens, Greece.
Kostas StylianouDepartment of Nephrology, University of Crete, Heraklion, Greece.
Hariklia GakiopoulouFirst Department of Pathology, National and Kapodistrian University of Athens Medical School, Athens, Greece.
George LiapisFirst Department of Pathology, National and Kapodistrian University of Athens Medical School, Athens, Greece.
Georgios SakellaropoulosDepartment of Medical Physics and Bioinformatics, University of Patras, Patras, Greece.
Evangelos PapachristouDepartment of Nephrology and Kidney Transplantation, University Hospital of Patras, Patras, Greece.
Ioannis BoletisDepartment of Nephrology and Kidney Transplantation, Laiko General Hospital of Athens, National and Kapodistrian University of Athens Medical School, Athens, Greece.
Aikaterini PapagianniDepartment of Nephrology, Hippokration General Hospital, Aristotle University of Thassaloniki, Thessaloniki, Greece.
Dimitrios S GoumenosDepartment of Nephrology and Kidney Transplantation, University Hospital of Patras, Patras, Greece.
Hippocration General Hospital · GRNational and Kapodistrian University of Athens · GRGeneral University Hospital of Patras · GRChania General Hospital ”St. George” · GRGeneral Hospital of Athens G. Genimatas · GRGeneral Hospital of Nikea · GRLaiko General Hospital of Athens · GRUniversity of Ioannina · GRUniversity of Patras · GRThe General Hospital of Heraklion "Venizeleio-Pananio" · GRUniversity of Crete · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundImmunoglobulin A nephropathy (IgAN) is among the commonest glomerulonephritides in Greece and an important cause of end-stage kidney disease (ESKD) with an insidious chronic course. Thus, the recently published International IgAN prediction tool could potentially provide valuable risk stratification and guide the appropriate treatment module. This study aimed to externally validate this prediction tool using a patient cohort from the IgAN registry of the Greek Society of Nephrology.

methodsWe validated the predictive performance of the two full models (with or without race) derived from the International IgAN Prediction Tool study in the Greek Society of Nephrology registry of patients with IgAN using external validation of survival prediction models (Royston and Altman). The discrimination and calibration of the models were tested using the C-statistics and stratified analysis, coefficient of determination (

resultsThe study included 264 patients with a median age of 39 (30-51) years where 65.2% are men. All patients were of Caucasian origin. The 5-year risk of the primary outcome (50% reduction in estimated glomerular filtration rate or ESKD) was 8%. The

conclusionsThe two full models with or without race were shown to accurately distinguish the highest and higher risk patients from patients with low and intermediate risk for disease progression in the Greek registry of IgAN.

Indexed as

ACE inhibitorschronic kidney diseaseIgAN disease progressionIgAN prediction toolimmunosuppression

Identifiers

PMID35242773
PMCPMC8885590
OpenAlexW4213096014

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.